NCT03525210View on ClinicalTrials.gov

Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

271

Participants

Timeline

Start Date

April 4, 2018

Primary Completion Date

September 1, 2019

Study Completion Date

July 15, 2020

Conditions
Human Papilloma VirusHivOrgan Transplants
Interventions
BIOLOGICAL

9-valent HPV vaccine

Vaccination

Trial Locations (1)

3000

UZ Leuven, Leuven

All Listed Sponsors
lead

Universitaire Ziekenhuizen KU Leuven

OTHER

NCT03525210 - Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients | Biotech Hunter | Biotech Hunter